MicroVision, Inc.
9.5.2024 22:07:59 CEST | ACCESS Newswire | Press release
REDMOND, WA / ACCESSWIRE / May 9, 2024 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its first quarter 2024 results.
Key Business Highlights for Q1 2024
- Actively engaged in high-volume, top-tier global OEM RFQs for passenger vehicles.
- Expanding near-term revenue opportunities through direct sales in industrial markets.
- Working to accumulate non-dilutive cash by leveraging partnerships and licensing opportunities.
- Increasing cash runway through proactive, disciplined fiscal management.
"Energized by global OEM feedback that MicroVision offers the best technical and commercial solutions, we remain confident in our engagement with automotive OEMs and our prospects in high-volume, top-tier, passenger-vehicle RFQs," said Sumit Sharma, MicroVision's Chief Executive Officer. "As we navigate current headwinds in the automotive industry and lidar sector with a healthy balance of optimism and realism, we are aggressively pursuing near-term revenue opportunities in industrial markets and with partnership opportunities, as well as continuing our ethos of fiscal discipline."
"I remain committed to steering MicroVision and firmly establishing it as a leading automotive OEM supplier of lidar hardware and software solutions," continued Sharma.
Key Financial Highlights for Q1 2024
- Revenue for the first quarter of 2024 was $1.0 million, compared to $0.8 million for the first quarter of 2023 primarily driven by sales of MOVIA sensors to a global commercial trucking OEM.
- Net loss for the first quarter of 2024 was $26.3 million, or $0.13 per share, which includes $3.7 million of non-cash, share-based compensation expense, compared to a net loss of $19.0 million, or $0.11 per share, which includes $2.9 million of non-cash, share-based compensation expense, for the first quarter of 2023.
- Adjusted EBITDA for the first quarter of 2024 was a $18.7 million loss, compared to a $15.7 million loss for the first quarter of 2023.
- Cash used in operations in the first quarter of 2024 was $20.8 million, compared to cash used in operations in the first quarter of 2023 of $13.5 million.
- The Company ended the first quarter of 2024 with $73.1 million in cash and cash equivalents including investment securities, compared to $73.8 million at December 31, 2023.
Conference Call and Webcast: Q1 2024 Results
MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 1:30 PM PT/4:30 PM ET on Thursday, May 9, 2024 to discuss the financial results and provide a business update. Analysts and investors may pose questions to management during the live webcast on May 9, 2024.
The live webcast and slide presentation can be accessed on the Company's Investor Relations website under the Events tab at https://ir.microvision.com/events. The webcast will be archived on the website for future viewing.
About MicroVision
With offices in the U.S. and Germany, MicroVision is a pioneering company in MEMS-based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company's integrated approach uses its proprietary technology to provide automotive lidar sensors and solutions for advanced driver-assistance systems (ADAS) and for non-automotive applications including industrial, smart infrastructure and robotics. The Company has been leveraging its experience building augmented reality micro-display engines, interactive display modules, and consumer lidar modules.
For more information, visit the Company's website at www.microvision.com, on Facebook at www.facebook.com/microvisioninc, and LinkedIn at https://www.linkedin.com/company/microvision/.
MicroVision, MAVIN, MOSAIK, and MOVIA are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.
Non-GAAP information
To supplement MicroVision's condensed financial statements presented in accordance with GAAP, the Company presents investors with the non-GAAP financial measures "adjusted EBITDA" and "adjusted Gross Profit." Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; bargain purchase gain; share-based compensation; and restructuring charges. Adjusted Gross Profit is calculated as GAAP gross profit before share-based compensation expense and the amortization of acquired intangibles included in cost of revenue.
MicroVision believes that the presentation of adjusted EBITDA and adjusted Gross Profit provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision's past financial reports, and facilitates comparisons with other companies in the Company's industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses these non-GAAP measures when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company's operating results and facilitates comparisons of the Company's core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA and adjusted Gross Profit are useful to investors in their assessment of MicroVision's operating performance and the valuation of the Company.
Adjusted EBITDA and adjusted Gross Profit are not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision's business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from its non-GAAP financial measures should not be construed as an inference that these costs are unusual or infrequent.
The Company compensates for limitations of the adjusted EBITDA measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.
Similarly for Adjusted Gross Profit, the Company compensates for limitations of the measure by prominently disclosing GAAP gross profit which is the difference between Revenue and Cost of revenue, which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation by backing out share-based compensation expense and the amortization of acquired intangibles included in cost of revenue.
Forward-Looking Statements
Certain statements contained in this release, including customer engagement and the likelihood of success, opportunities for revenue and cash, expense reduction, market position, product portfolio, product and manufacturing capabilities, and expected revenue, expenses and cash usage are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements; its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.
Investor Relations Contact
Jeff Christensen
Darrow Associates Investor Relations
MVIS@darrowir.com
Media Contact
Microvision, Inc.
Consolidated Balance Sheet
(In thousands)
(Unaudited)
| March 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
Assets | ||||||||
Current Assets | ||||||||
Cash and cash equivalents | $ | 44,298 | $ | 45,167 | ||||
Investment securities, available-for-sale | 28,770 | 28,611 | ||||||
Restricted cash, current | 71 | 3,263 | ||||||
Accounts receivable, net of allowances | 1,121 | 949 | ||||||
Inventory | 3,738 | 3,874 | ||||||
Other current assets | 4,302 | 4,890 | ||||||
Total current assets | 82,300 | 86,754 | ||||||
Property and equipment, net | 8,549 | 9,032 | ||||||
Operating lease right-of-us asset | 13,212 | 13,758 | ||||||
Restricted cash, net of current portion | 1,968 | 961 | ||||||
Intangible assets, net | 16,662 | 17,235 | ||||||
Other assets | 1,491 | 1,895 | ||||||
Total assets | $ | 124,182 | $ | 129,635 | ||||
Liabilities and Shareholders' Equity | ||||||||
Current Liabilities | ||||||||
Accounts payable | $ | 2,161 | $ | 2,271 | ||||
Accrued liabilities | 9,971 | 8,640 | ||||||
Accrued liability for Ibeo business combination | 2,969 | 6,300 | ||||||
Contract liabilities | 213 | 300 | ||||||
Current portion of operating lease liability | 2,167 | 2,323 | ||||||
Other current liabilities | 270 | 669 | ||||||
Total current liabilities | 17,751 | 20,503 | ||||||
Operating lease liability, net of current portion | 12,358 | 12,714 | ||||||
Other long-term liabilities | 270 | 614 | ||||||
Total liabilities | 30,379 | 33,831 | ||||||
Commitments and contingencies | ||||||||
Shareholders' Equity | ||||||||
Common stock at par value | 206 | 195 | ||||||
Additional paid-in capital | 885,119 | 860,765 | ||||||
Accumulated other comprehensive loss | 157 | 210 | ||||||
Accumulated deficit | (791,679 | ) | (765,366 | ) | ||||
Total shareholders' equity | 93,803 | 95,804 | ||||||
Total liabilities and shareholders' equity | $ | 124,182 | $ | 129,635 | ||||
MicroVision, Inc.
Consolidated Statement of Operations
(In thousands, except earnings per share data)
(Unaudited)
| Three months ended March 31, | ||||||||
| 2024 | 2023 | |||||||
Revenue | $ | 956 | $ | 782 | ||||
Cost of revenue | 1,277 | 544 | ||||||
Gross profit | (321 | ) | 238 | |||||
Research and development expense | 17,311 | 12,692 | ||||||
Sales, marketing, general and administrative expense | 9,078 | 8,737 | ||||||
Total operating expenses | 26,389 | 21,429 | ||||||
Loss from operations | (26,710 | ) | (21,191 | ) | ||||
Bargain purchase gain | - | 1,706 | ||||||
Other income, net | 631 | 639 | ||||||
Net loss before taxes | $ | (26,079 | ) | $ | (18,846 | ) | ||
Income tax expense | (234 | ) | (181 | ) | ||||
Net income (loss) | $ | (26,313 | ) | $ | (19,027 | ) | ||
Net income (loss) per share - basic and diluted | $ | (0.13 | ) | $ | (0.11 | ) | ||
Weighted-average shares outstanding - basic and diluted | 196,748 | 174,703 | ||||||
Microvision, Inc.
Consolidated Statement of Cash Flows
(In thousands)
(Unaudited)
| Three months ended March 31, | ||||||||
| 2024 | 2023 | |||||||
Cash flows from operating activities | ||||||||
Net loss | $ | (26,313 | ) | $ | (19,027 | ) | ||
Adjustments to reconcile net loss to | ||||||||
net cash used in operations | ||||||||
Depreciation and amortization | 1,800 | 2,524 | ||||||
Impairment of property and equipment | 13 | - | ||||||
Bargain purchase gain | - | (1,706 | ) | |||||
Share-based compensation expense | 3,743 | 2,949 | ||||||
Inventory write-down | 9 | 29 | ||||||
Net accretion of premium on short-term investments | (288 | ) | (396 | ) | ||||
Change in: | ||||||||
Accounts receivable | (172 | ) | (506 | ) | ||||
Contract assets | - | (192 | ) | |||||
Inventory | 102 | (87 | ) | |||||
Other current and non-current assets | 992 | 647 | ||||||
Accounts payable | (527 | ) | 1,629 | |||||
Accrued liabilities | 1,331 | 2,017 | ||||||
Contract liabilities and other current liabilities | (480 | ) | (711 | ) | ||||
Operating lease liabilities | (639 | ) | (669 | ) | ||||
Other long-term liabilities | (330 | ) | 17 | |||||
Net cash used in operating activities | (20,759 | ) | (13,482 | ) | ||||
Cash flows from investing activities | ||||||||
Sales of investment securities | 7,900 | 22,000 | ||||||
Purchases of investment securities | (7,805 | ) | (3,898 | ) | ||||
Purchases of property and equipment | (114 | ) | (615 | ) | ||||
Cash paid for Ibeo business combination | (3,263 | ) | (11,233 | ) | ||||
Net cash provided by (used in) investing activities | (3,282 | ) | 6,254 | |||||
Cash flows from financing activities | ||||||||
Principal payments under finance leases | - | (6 | ) | |||||
Proceeds from stock option exercises | 62 | - | ||||||
Net proceeds from issuance of common stock | 20,956 | 12,691 | ||||||
Net cash provided by financing activities | 21,018 | 12,685 | ||||||
Effect of exchange rate changes on cash and cash equivalents | (31 | ) | - | |||||
Net increase (decrease) in cash and cash equivalents | (3,054 | ) | 5,457 | |||||
Cash, cash equivalents and restricted cash at beginning of period | 49,391 | 21,954 | ||||||
Cash, cash equivalents and restricted cash at end of period | $ | 46,337 | $ | 27,411 | ||||
| The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of | ||||||||
March 31, 2024 and December 31, 2023: | ||||||||
| March 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
Cash and cash equivalents | $ | 44,298 | $ | 45,167 | ||||
Restricted cash | 2,039 | 4,224 | ||||||
Cash, cash equivalents and restricted cash | 46,337 | 49,391 | ||||||
MicroVision, Inc.
Reconciliation of GAAP to Non-GAAP Measures
(In thousands, except earnings per share data)
(Unaudited)
| Three months ended March 31, | ||||||||
| 2024 | 2023 | |||||||
Reconciliation of Non-GAAP Gross Profit: | ||||||||
Gross Profit | $ | (321 | ) | $ | 238 | |||
Share-based compensation expense | - | - | ||||||
Amortization of acquired intangibles | 387 | 255 | ||||||
Adjusted Gross Profit | $ | 66 | $ | 493 | ||||
Reconciliation of Non-GAAP Loss: | ||||||||
GAAP Net loss | $ | (26,313 | ) | $ | (19,027 | ) | ||
Other Income/Expense,net | (631 | ) | (639 | ) | ||||
Income taxes | 234 | 181 | ||||||
Depreciation & amortization | 1,800 | 2,524 | ||||||
Bargain purchase gain | - | (1,706 | ) | |||||
Share-based compensation expense | 3,743 | 2,949 | ||||||
Restructuring costs | 2,474 | - | ||||||
Adjusted EBITDA | $ | (18,693 | ) | $ | (15,718 | ) | ||
SOURCE: MicroVision, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Iggy Azalea Invests in Shift - The AI Company Behind the Fastest-Growing Platform in the $1.3 Trillion Creator Economy, Fanvue27.8.2026 14:00:00 CEST | Press release
The Grammy-nominated artist and entrepreneur has made a significant investment in SHIFT, whose AI infrastructure has propelled its flagship platform, Fanvue, from a $4m to $200m annualised run rate in just over 2 years. LONDON, UK / ACCESS Newswire / August 27, 2026 / Iggy Azalea, the four-time Grammy-nominated artist, entrepreneur, and active investor, has personally invested a substantial sum in Fanvue's parent company SHIFT - the AI infrastructure the platform runs on. As part of the investment deal, Azalea will also become the founding member of SHIFT's Creator Advisory Board. The move comes at a time when the world's biggest creators, athletes and music artists are increasingly looking to multi-million-dollar equity opportunities in the creator economy - recent examples include MrBeast and the Paul brothers, Jake and Logan. AI is transforming how people make money online. For two decades, the creator economy has run on a simple trade: creators build the audience, and advertisers r
ZAGENO and ORO Labs Partner to Connect Scientific Purchasing with Enterprise Procurement26.8.2026 14:35:00 CEST | Press release
Partnership combines ORO Labs' AI-native procurement orchestration platform with ZAGENO's scientific marketplace and supplier network to deliver a governed, end-to-end purchasing experience for life sciences R&D. BOSTON, MA / ACCESS Newswire / August 26, 2026 / ZAGENO, the scientific procurement platform connecting researchers with 75 million laboratory products from approximately 5,500 suppliers, today announced a strategic partnership with ORO Labs, the AI-native procurement orchestration platform. The partnership connects ORO Labs' enterprise intake, workflow, and approval capabilities with ZAGENO's scientific product discovery, marketplace, supplier network, and fulfillment infrastructure. Together, the companies enable a single governed journey from request and approval through product selection, ordering, and fulfillment. Scientific R&D procurement has specialized requirements. Researchers need fast, intuitive access to highly specific products, while procurement teams need polic
Eudia Accelerates Enterprise AI Transformation with Google Cloud's Gemini Enterprise for Legal25.8.2026 15:50:00 CEST | Press release
PALO ALTO, CA / ACCESS Newswire / August 25, 2026 / Eudia, the augmented intelligence platform for enterprise legal, contracting, and compliance, today announced a partnership with Google to launch new industry-specific AI capabilities on Google Cloud's Gemini Enterprise for Legal. Eudia's agent scales the legal, contracting, and compliance expertise of an organization's top operators to every team in the enterprise. Built on Google's Agent Development Kit and connected via MCP, Eudia combines a suite of specialized agents with digital twins of domain-scoped institutional knowledge, orchestrated with legal-specific reasoning and access to legal databases. Eudia enables Legal, Compliance, Procurement, and Revenue teams to draft and review contracts, analyze marketing assets for compliance, assess risk across thousands of executed contracts, and manage obligations across the entire company portfolio, giving large enterprises a faster path to trusted, governed legal AI. In practice, this
Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth25.8.2026 15:00:00 CEST | Press release
New role unifies sales enablement, lead generation, and marketing under centralized leadership and expands oversight to customer success, supporting a consistent, connected client experience across Envision. FAIRFIELD, CT / ACCESS Newswire / August 25, 2026 / Envision Pharma Group (Envision) has appointed Ryan Tubbs as Senior Vice President, Commercial Growth. In this newly created role, Tubbs will lead the centralized Commercial Growth function spanning sales enablement, lead generation, marketing, and client success. He will also help shape Envision's commercial strategy and operating model to accelerate enterprise growth. Tubbs' remit also includes the Client Implementation and Client Experience teams. Connecting Envision's pre-sale and post-sale capabilities will create a more integrated commercial engine, making it easier for teams to bring the best of Envision to clients and for clients to realize value quickly. The timing is notable as Envision's iEnvision®, market access, and m
Polaris Renewable Energy Announces Renewal of Normal Course Issuer Bid25.8.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / August 25, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") today announced that the Toronto Stock Exchange ("TSX") has accepted its notice of intention to renew its normal course issuer bid ("NCIB"). The Company's Board of Directors believes that an NCIB represents an appropriate and desirable use of its available free cash to increase shareholder value and is in the best interest of the Company and its shareholders. Pursuant to the notice, Polaris may purchase up to 2,021,205 of its common shares ("Shares"), representing approximately 10% of the public float of 20,212,059 Shares as at August 13, 2026, during the twelve month period commencing August 27, 2026 and ending August 26, 2027, provided that the board of directors of Polaris has initially limited the NCIB to repurchase up to 176,872 Shares. As at August 13, 2026, there were 20,895,285 Shares issued and outstanding. Under the NCIB, other than purchases made under block
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
